In the last 12 months, insiders at Elicio Therapeutics neither bought nor sold shares on the open market.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Yekaterina Chudnovsky | Director, TenPercentOwner | 0 | 5,416,212 | 5,416,212 | 90.4% | 06 Mar, 2025 |
| 2 | Jay Venkatesan | Director | 179,581 | 0 | 179,581 | 3.0% | 29 Nov, 2024 |
| 3 | Itzhak Goldberg | Director | 168,799 | 0 | 168,799 | 2.8% | 11 Jul, 2022 |
| 4 | Robert Connelly | Ceo, President And Director | 120,570 | 0 | 120,570 | 2.0% | 03 Feb, 2026 |
| 5 | Christopher Haqq | Officer | 57,381 | 0 | 57,381 | 1.0% | 03 Feb, 2026 |
| 6 | Preetam Shah | Officer | 24,000 | 0 | 24,000 | 0.4% | 03 Feb, 2026 |
| 7 | Peter Demuth | Chief Scientific Officer | 21,543 | 0 | 21,543 | 0.4% | 03 Feb, 2026 |
| 8 | Allen Nissenson | Director | 938 | 0 | 938 | 0.0% | 23 May, 2022 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 31 Aug, 2026 | Allen Nissenson | Director | Acquired A | 21,750 | $0.00 | $0 | 21,750 | Direct |
| 31 Aug, 2026 | Karen J Wilson | Director | Acquired A | 21,750 | $0.00 | $0 | 21,750 | Direct |
| 31 Aug, 2026 | Julian Adams | Director | Acquired A | 21,750 | $0.00 | $0 | 21,750 | Direct |
| 31 Aug, 2026 | Carol Gail Ashe | Director | Acquired A | 21,750 | $0.00 | $0 | 21,750 | Direct |
| 31 Aug, 2026 | Jay Venkatesan | Director | Acquired A | 21,750 | $0.00 | $0 | 21,750 | Direct |
| 31 Aug, 2026 | Yekaterina Chudnovsky | Director, TenPercentOwner | Acquired A | 21,750 | $0.00 | $0 | 21,750 | Direct |
| 31 Aug, 2026 | Robert R Ruffolo | Director | Acquired A | 21,750 | $0.00 | $0 | 21,750 | Direct |
| 16 Jul, 2026 | Peter Demuth | Chief Scientific Officer | Acquired A | 52,832 | $0.00 | $0 | 52,832 | Direct |
| 16 Jul, 2026 | Robert Connelly | Ceo, President And Director | Acquired A | 186,944 | $0.00 | $0 | 186,944 | Direct |
| 16 Jul, 2026 | Christopher Haqq | Officer | Acquired A | 64,643 | $0.00 | $0 | 64,643 | Direct |
| 16 Jul, 2026 | Preetam Shah | Officer | Acquired A | 60,833 | $0.00 | $0 | 60,833 | Direct |
| 02 Feb, 2026 | Preetam Shah | Officer | Acquired A | 24,000 | $0.00 | $0 | 24,000 | Direct |
| 02 Feb, 2026 | Christopher Haqq | Officer | Acquired A | 25,400 | $0.00 | $0 | 57,381 | Direct |
| 02 Feb, 2026 | Peter Demuth | Chief Scientific Officer | Acquired A | 20,800 | $0.00 | $0 | 21,543 | Direct |
| 02 Feb, 2026 | Robert Connelly | Ceo, President And Director | Acquired A | 73,600 | $0.00 | $0 | 120,570 | Direct |
| 02 Feb, 2026 | Christopher Haqq | Officer | Acquired A | 50,900 | $0.00 | $0 | 50,900 | Direct |
| 02 Feb, 2026 | Robert Connelly | Ceo, President And Director | Acquired A | 147,200 | $0.00 | $0 | 147,200 | Direct |
| 02 Feb, 2026 | Peter Demuth | Chief Scientific Officer | Acquired A | 41,600 | $0.00 | $0 | 41,600 | Direct |
| 02 Feb, 2026 | Preetam Shah | Officer | Acquired A | 47,900 | $0.00 | $0 | 47,900 | Direct |
| 09 Dec, 2025 | Peter Demuth | Chief Scientific Officer | Acquired M | 362 | $4.41 | $1.60K | 743 | Direct |